11 Jun. 2010
WILMINGTON, N.C. (June 11, 2010) - PPD, Inc. (Nasdaq: PPDI) today announced it has been rated one of Europe's top contract research organizations (CROs) in the 2010 CenterWatch European Site Survey. The company earned a number two ranking among CROs with 78.4 percent of participants rating PPD's overall relationship quality as "excellent" or "good."
PPD scored among the top three in 26 of the 29 survey attributes and received the highest marks of any CRO for being organized and prepared, an attribute considered important for clinical trial study success. PPD also rated highest for its work style and supportive culture and scored well in study initiation and ongoing conduct, staff professionalism and grant payment process.
"We value our strong, collaborative relationships with investigative sites across the globe and consider them our partners in drug development," said Sebastian Pacios, M.D., senior vice president of clinical development for Europe, Middle East and Africa. "Through our specialized project teams, we work closely with investigators to recruit the right patients and deliver accurate, reliable study data for our clients."
Nearly 1,000 respondents from 30 countries completed the survey, which was conducted this past January through March. Principal investigators comprised 77 percent of respondents while 13 percent were sub-investigators, and the remaining responses were study coordinators and nurses.
The survey is conducted by CenterWatch, a leading publishing and information services company focused on the clinical trials industry. The European survey is conducted every two years and includes input from clinical research professionals at biopharmaceutical companies, CROs and investigative sites.